For tumor-associated antigens (TAAs), the development of a CTL response relies on antigen cross-presentation, a process during which the transformed or over-expressed antigens expressed by tumor cells are captured, processed and cross-presented to CD8+ T cells by professional antigen-presenting cells (pAPCs), such as dendritic cells (DCs) [3,4]. This evidence concerns the gene CD8A and neoplasm.